Cellectis

Cellectis is a clinical-stage biopharmaceutical company dedicated to developing life-saving cell and gene therapies using its pioneering gene-editing platform. Their flagship technology, TALEN®, allows for precise edits to the genome of any organism, providing a powerful tool for developing innovative therapies. Cellectis leverages TALEN® to create CAR T therapies, which are immune cells engineered to target and destroy cancer cells.

Cellectis is committed to developing "off-the-shelf" CAR T therapies, which can be readily available to a broad patient population. This approach is in contrast to traditional CAR T therapies, which are customized for each patient, making them more expensive and time-consuming. Cellectis is also developing a novel electroporation system called PulseAgile, which allows for efficient delivery of gene editing tools into cells. These technologies are being used to develop therapies for a range of blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

Cellectis offers a comprehensive suite of benefits to its employees, including competitive health insurance, company benefits, and a commitment to employee wellbeing. These benefits are designed to attract and retain top talent, ensuring that employees feel valued and supported in all aspects of their lives.

Cellectis is a clinical-stage biopharmaceutical company focused on harnessing the power of the immune system to target and eradicate cancer cells. With 24 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile, Cellectis is developing a new generation of allogeneic CAR T immunotherapies. Their mission is to provide life-saving therapies for patients with unmet medical needs in the field of oncology, by pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells. Cellectis is committed to delivering life-changing product candidates to address various cancers, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

Cellectis promotes a culture of collaboration, ingenuity, and dedication. The company values the diverse perspectives of its employees and believes that teamwork is essential for success. Cellectis prioritizes an environment of trust and transparency, where everyone feels comfortable sharing ideas and working towards a common goal: developing innovative therapies to improve patient lives.

Cellectis emphasizes diversity, equity and inclusion as fundamental to its success and innovation. The company actively seeks to build an inclusive workplace that empowers all employees to bring their unique perspectives and passions to their work. This commitment to diversity is reflected in its workforce, which draws talent from over 15 countries and its focus on creating a safe and respectful environment where all voices are heard. Cellectis is committed to fair hiring practices, providing equal opportunities for all, and fostering a collaborative environment that allows for career development and the realization of individual potential.